NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for two additional patent applications. The allowed patents provide fundamental coverage on physiologic microdroplet ejection diameters and velocities, which enable gentle delivery of ophthalmic therapeutics to the eye at velocities that beat the eye’s blink reflex.

Once issued, the new patents will complement Eyenovia’s existing intellectual property portfolio and are expected to further strengthen the Company’s position as a leader in micro-therapeutic ophthalmic delivery with a total of 8 issued US patents and 27 issued and allowed international patents.

Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer commented, “We are pleased that the USPTO continues to recognize the novel features of our piezo-print technology that has the ability to gently and efficiently deliver micro-therapeutic solutions to the eye. With an expanding global intellectual property portfolio, we look forward to advancing our late stage clinical assets for mydriasis, glaucoma and myopia into Phase 3 development.”

About EyenoviaEyenovia, Inc. (NASDAQ:EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.

Forward Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements could be affected by risks and uncertainties related to, among other things: intellectual property risks; risks involved in clinical trials, including, but not limited to, the initiation, timing, progress and results of such trials; the timing and our ability to submit applications for, obtain and maintain regulatory approvals for, our product candidates; our ability to implement our business plan to commercialize our product candidates; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; our current lack of commercialization, marketing and manufacturing capabilities and strategy; our ability to attract and retain key personnel; our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives; our expectations regarding our ability to fund our operating expenses and capital expenditure requirements; the impact of government laws and regulations; our competitive position; and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, we do not undertake any obligation to update any forward-looking statements.

Company Contact:Eyenovia Inc.John GandolfoChief Financial Officer jgandolfo@eyenoviabio.com

Investor Contact:Tram Bui / Alexander LoboThe Ruth GroupPhone: 646-536-7035/7037E-mail: tbui@theruthgroup.com / alobo@theruthgroup.com

Media Contact:The Ruth GroupKirsten Thomas508-280-6592 kthomas@theruthgroup.com